Two Sigma Advisers
GLUE icon

Two Sigma Advisers’s Monte Rosa Therapeutics GLUE Stock Holding History

Two Sigma Advisers’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,100
Closed -$82.3K – 2446
2025
Q3 		$82.3K Sell
11,100
-61,400
-85% -$325K ﹤0.01% 2240
2025
Q2 		$327K Buy
+72,500
New +$323K ﹤0.01% 1926
2025
Q1 		– Sell
-26,000
Closed -$180K – 2461
2024
Q4 		$180K Buy
+26,000
New +$195K ﹤0.01% 2141

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's GLUE Position: Q4 2025 in Review

Two Sigma Advisers sold out of Monte Rosa Therapeutics (GLUE) in Q4 2025, closing a stake of 11,100 shares — an estimated $82.3K sold.

Two Sigma Advisers first reported a position in GLUE in Q4 2024 and held it in 3 quarters. The position peaked at $327K in Q2 2025. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Two Sigma Advisers reported no remaining Monte Rosa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 11,100 Monte Rosa Therapeutics shares in Q4 2025, an estimated $82.3K.
  • Two Sigma Advisers first reported a position in Monte Rosa Therapeutics in Q4 2024 and held it in 3 quarters.
  • Two Sigma Advisers's Monte Rosa Therapeutics position peaked at $327K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.